HOOKライブシグナル | Getagraph.comで利益を最大化

売る 108131 min ago

@ $0.697

発行日: 14 2月 2024 @ 23:37

リターン: 46.31%

前回のシグナル: 2月 13 - 04:32

前回のシグナル: 買う

リターン: 4.84 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:47):

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform...

Stats
本日の出来高	1.48M
平均出来高	752 017
時価総額	98.49M
EPS	$0 ( 2024-03-20 )
次の収益日	( $-0.120 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.190
ATR14	$0.00600 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Orlinger Klaus	Buy	367 300	Stock Option (Right to Buy)
2024-04-15	Aldag Jorn	Buy	971 400	Stock Option (Right to Buy)
2024-04-15	Winderlich Mark	Buy	250 000	Stock Option (Right to Buy)
2024-04-15	Winderlich Mark	Buy	50 000	Stock Option (Right to Buy)
2024-04-15	Kandera Reinhard	Buy	406 200	Stock Option (Right to Buy)

INSIDER POWER
98.82
Last 94 transactions
Buy: 7 455 375 \| Sell: 565 370

ボリューム相関

長: 0.50 (neutral)

短: 0.40 (neutral)

Signal:(72.289) Neutral

HOOKIPA Pharma Inc 相関

10 最も正の相関
TCRT	0.916
VSTA	0.914
JNCE	0.904
INFI	0.903
MPAA	0.903
VCSA	0.902
POWW	0.899
VIRX	0.899
GRAY	0.897
TOI	0.896

10 最も負の相関
IMMR	-0.897
PBFS	-0.892
BNIXU	-0.887
ISIG	-0.875
WEN	-0.873
CCRC	-0.872
MGI	-0.869
SEDG	-0.864
IBEX	-0.862
MSON	-0.859

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

HOOKIPA Pharma Inc 相関 - 通貨/商品

-0.15
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.65
( weak negative )

0.40
( neutral )

HOOKIPA Pharma Inc 財務諸表

Annual	2023
収益:	$20.13M
総利益:	$16.58M (82.35 %)
EPS:	$-0.860

FY	2023
収益:	$20.13M
総利益:	$16.58M (82.35 %)
EPS:	$-0.860

FY	2022
収益:	$14.25M
総利益:	$10.65M (74.72 %)
EPS:	$-0.990

FY	2021
収益:	$18.45M
総利益:	$18.45M (100.00 %)
EPS:	$-2.79

Financial Reports:

No articles found.

HOOKIPA Pharma Inc

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.